Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

A Novel Therapeutic Approach In Acute Myeloid Leukemia (AML): In Vivo Preclinical Pharmacokinetic (PK), Pharmacodynamic (PD) and Antileukemia Activities Of Synthetic 2’-O-Methylphosphorothioate Mir-29b

Hongyan Wang, PhD, Ramasamy Santhanam, Ph.D, Zhiliang Xie, MD, Xiaomeng Huang, Ming Chiu, Mitch A. Phelps, PhD, Alison R Walker, MD, Michael A. Caligiuri, MD, Ramiro Garzon, MD, James Lee, PhD, Natarajan Muthusamy, DVM, Ph.D, Kenneth K. Chan, Ph.D, Guido Marcucci, MD

Blood (2013) 122 (21): 3933.

https://doi.org/10.1182/blood.V122.21.3933.3933

Published: 2013

Journal Articles

Decitabine Priming Enhances The Antileukemic Effects Of The Selective Inhibitor Of Nuclear Export (SINE) CRM1/XPO1 Antagonist (Selinexor) In Acute Myeloid Leukemia (AML)

Parvathi Ranganathan, Ph.D, Xueyan Yu, Ph.D, Jessica Hofstetter, BS, Ramasamy Santhanam, Ph.D, Sharon Schacham, PhD, MBA, Michael Kauffman, MD, PhD, William Blum, MD, Guido Marcucci, MD, Ramiro Garzon, MD

Blood (2013) 122 (21): 1453.

https://doi.org/10.1182/blood.V122.21.1453.1453

Published: 2013

Journal Articles

Therapeutic Targeting of the RAS-Pathway by Synthetic Mir-181a Nanoparticles in Acute Myeloid Leukemia (AML).

Blood (2012) 120 (21): 2422.

https://doi.org/10.1182/blood.V120.21.2422.2422

Published: 2012

Journal Articles

Quantification of the Active Decitabine-Triphosphate (DAC-TP) Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (AML)

Hongyan Wang, Ping Chen, Ph.D., Jiang Wang, Ramasamy Santhanam, Ph.D, Josephine Aimiuwu, Vijayasaradhi UV, Zhongfa Liu, Sebastian Schwind, MD, Alice S. Mims, MD, Rebecca B Klisovic, MD, Alison Walker, MD, Michael R. Grever, MD, Miguel Villalona-Calero, MD, John C. Byrd, MD, Ramiro Garzon, MD, William Blum, MD, Kenneth K. Chan, Ph.D, Guido Marcucci, MD

Blood (2012) 120 (21): 3578.

https://doi.org/10.1182/blood.V120.21.3578.3578

Published: 2012

Journal Articles

Anti-Leukemic Activity of the CRM1 Inhibitor KPT-330 in Advanced CML and Ph+ ALL

Christopher J Walker, Joshua J Oaks, Ramasamy Santhanam, Ph.D, Paolo Neviani, Ph.D, Jason G Harb, Ph.D, Gregory Ferenchak, Justin Ellis, Guido Marcucci, MD, Yosef Landesman, PhD, Sharon Shacham, PhD MBA, Michael Kauffman, MD, PhD, Danilo Perrotti, MD, Ph.D

Blood (2012) 120 (21): 35.

https://doi.org/10.1182/blood.V120.21.35.35

Published: 2012

Journal Articles

SPARC contributes to Leukemia Growth and Aggressive Disease in Acute Myeloid Leukemia (AML)

Blood (2012) 120 (21): 773.

https://doi.org/10.1182/blood.V120.21.773.773

Published: 2012

Journal Articles

Targeted Delivery of MicroRNA-29b by Nanoparticles Provides Antileukemic Activity and Increases Sensitivity to the Hypomethylating Agent Decitabine (DAC) in Acute Myeloid Leukemia (AML)

Xiaomeng Huang, Sebastian Schwind, MD, Bo Yu, Ph.D, Jiuxia Pang, Ramasamy Santhanam, Ph.D, Kenneth K. Chan, Ph.D, Ramiro Garzon, MD, William Blum, MD, Clara D. Bloomfield, MD, Shujun Liu, Ph.D, Danilo Perrotti, MD, Ph.D, Robert J. Lee, Ph.D, John C. Byrd, MD, Natarajan Muthusamy, DVM, Ph.D, L. James Lee, Ph.D, Guido Marcucci, MD

Blood (2011) 118 (21): 81.

https://doi.org/10.1182/blood.V118.21.81.81

Published: 2011

Journal Articles

Nuclear Export (Karyopherin) Inhibitors: A Novel Therapeutic Strategy for Treating Blast Crisis Chronic Myelogenous Leukemia (CML) and Philadelphia-Positive (Ph + ) Acute Lymphoblastic Leukemia (ALL) Through Interference with hnRNP Nucleocytoplasmic Shuttling and Rescue of Protein Phosphatase 2A (PP2A) Tumor Suppressor Activity,

Christopher J Walker, Joshua J Oaks, Ramasamy Santhanam, Ph.D, Paolo Neviani, PhD, Jason G Harb, Ph.D, Carolyn Paisie, B.S., Guido Marcucci, MD, Sharon Shacham, PhD, Michael Kauffman, MD, Ph.D., Danilo Perrotti, MD, Ph.D

Blood (2011) 118 (21): 3758.

https://doi.org/10.1182/blood.V118.21.3758.3758

Published: 2011

Journal Articles

BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment

Blood (2010) 116 (21): 515.

https://doi.org/10.1182/blood.V116.21.515.515

Published: 2010

Journal Articles

PP2A Activating Drugs (PAD): Anti-Leukemic and Non-Toxic Activity of Two Novel and Non-Immunosuppressive FTY720 Derivatives

Christopher Walker, B.S., Joshua J Oaks, B.S., Paolo Neviani, Ph.D, Jason G Harb, Ph.D., Ramasamy Santhanam, Ph.D, Y. Ma, Guido Marcucci, MD, James Van Brocklyn, Ph.D, Ching-Shih Chen, Ph.D, Robert Bittman, Ph.D, Danilo Perrotti, MD, PhD

Blood (2010) 116 (21): 2901.

https://doi.org/10.1182/blood.V116.21.2901.2901

Published: 2010

Journal Articles

Activation of PP2A by FTY720 Inhibits Survival and Self-Renewal of the Ph(+) Chronic Myelogenous Leukemia (CML) CD34 + /CD38 − Stem Cell through the Simultaneous Suppression of BCR/ABL and BCR/ABL– independent Signals

Paolo Neviani, PhD, Ramasamy Santhanam, Ph.D, Yihui Ma, B.S., Guido Marcucci, MD, John C. Byrd, MD, Ching-Shih Chen, Ph.D, Jorge Cortes, MD, Michael A. Caligiuri, MD, Claudia Huettner, PhD, Ravi Bhatia, MD, Denis-Claude Roy, MD, Danilo Perrotti, MD, PhD

Blood (2008) 112 (11): 189.

https://doi.org/10.1182/blood.V112.11.189.189

Published: 2008

Journal Articles

Activating PP2A Tumor Suppressor Activity as a Potential Therapy for Treating Jak2 V617F-Driven Myeloproliferative Disorders.

Joshua J. Oaks, BS, Ramasamy Santhanam, Ph.D., Roger Briesewitz, Ph.D., Danilo Perrotti, MD, Ph.D.

Blood (2007) 110 (11): 3548.

https://doi.org/10.1182/blood.V110.11.3548.3548

Published: 2007

Journal Articles

Requirement of the E2F3 Transcription Factor for BCR/ABL Leukemogenesis.

Anna M. Eiring, BS, Paolo Neviani, D.Sci., Ramasamy Santhanam, Ph.D., Joshua J. Oaks, B.S., Ji Suk Chang, Ph.D., Carlo Gambacorti-Passerini, MD, Stefano Volinia, MD, Guido Marcucci, MD, Michael A. Caligiuri, MD, Gustavo W. Leone, Ph.D., Danilo Perrotti, MD, Ph.D.

Blood (2007) 110 (11): 33.

https://doi.org/10.1182/blood.V110.11.33.33

Published: 2007

Journal Articles

FTY720 (2-Amino-2-[2-(4-octylphenyl) ethyl] Propane 1, 3-diol hydrochloride), Mediates Cytotoxicity through Caspase Independent and Protein Phosphatase 2A Dependent Mechanisms in Chronic Lymphocytic Leukemia and Lymphoblastic Leukemia/Lymphoma.

Qing Liu, MS, Xiaobin Zhao, M.S., Frank Frissora, M.S., Yihui Ma, M.S., Ramasamy Santhanam, Ph.D., Danilo Perrotti, M.D.,Ph.D., Ching-Shih Chen, Ph.D., James T. Dalton, Ph.D., John C. Byrd, M.D., Natarajan Muthusamy, DVM.,Ph.D.

Blood (2006) 108 (11): 2095.

https://doi.org/10.1182/blood.V108.11.2095.2095

Published: 2006

Journal Articles

Molecular and Pharmacologic Suppression of MAPK Activity Rescues Differentiation of BCR/ABL + Myeloid Progenitors by Releasing C/EBPa from the Inhibitory Effect of hnRNP E2.

Ji-Suk Chang, PhD, Ramasamy Santhanam, Ph.D, Edward Briercheck, B.S., Anna Eiring, B.S., Rossana Trotta, Ph.D, Mario Notari, D.Sci, Denis-Claude Roy, M.D., Michael A. Caligiuri, M.D., Danilo Perrotti, MD, PhD

Blood (2006) 108 (11): 2240.

https://doi.org/10.1182/blood.V108.11.2240.2240

Published: 2006

Journal Articles

ReSETting PP2A Tumor Suppressor Activity Overcomes BCR/ABL Leukemogenic Potential in Blast Crisis CML.

Paolo Neviani, MS, Ramasamy Santhanam, Ph.D, Rossana Trotta, Ph.D, Mario Notari, MS, Bradley W. Blaser, BS, Ji-Suk Chang, Ph.D, Shujun Liu, Ph.D, Hsiaoyin Mao, MS, Joshua J. Oaks, BS, Denis C. Roy, MD, Mauro Valtieri, MD, Rebecca Bruner-Klisovic, MD, Michael A. Caligiuri, MD, Clara D. Bloomfield, MD, Guido Marcucci, MD, Danilo Perrotti, MD, PhD

Blood (2005) 106 (11): 1992.

https://doi.org/10.1182/blood.V106.11.1992.1992

Published: 2005

NARROW

A Novel Therapeutic Approach In Acute Myeloid Leukemia (AML): In Vivo Preclinical Pharmacokinetic (PK), Pharmacodynamic (PD) and Antileukemia Activities Of Synthetic 2’-O-Methylphosphorothioate Mir-29b

Decitabine Priming Enhances The Antileukemic Effects Of The Selective Inhibitor Of Nuclear Export (SINE) CRM1/XPO1 Antagonist (Selinexor) In Acute Myeloid Leukemia (AML)

Therapeutic Targeting of the RAS-Pathway by Synthetic Mir-181a Nanoparticles in Acute Myeloid Leukemia (AML).

Quantification of the Active Decitabine-Triphosphate (DAC-TP) Metabolite: A Novel Pharmacoanalytical Endpoint for Optimization of Hypomethylating Therapy in Acute Myeloid Leukemia (AML)

Anti-Leukemic Activity of the CRM1 Inhibitor KPT-330 in Advanced CML and Ph+ ALL

SPARC contributes to Leukemia Growth and Aggressive Disease in Acute Myeloid Leukemia (AML)

Targeted Delivery of MicroRNA-29b by Nanoparticles Provides Antileukemic Activity and Increases Sensitivity to the Hypomethylating Agent Decitabine (DAC) in Acute Myeloid Leukemia (AML)

BCR-ABL1 Kinase Activity but Not Its Expression Is Dispensable for Ph+ Quiescent Stem Cell Survival Which Depends on the PP2A-Controlled Jak2 Activation and Is Sensitive to FTY720 Treatment

PP2A Activating Drugs (PAD): Anti-Leukemic and Non-Toxic Activity of Two Novel and Non-Immunosuppressive FTY720 Derivatives

Activation of PP2A by FTY720 Inhibits Survival and Self-Renewal of the Ph(+) Chronic Myelogenous Leukemia (CML) CD34 + /CD38 − Stem Cell through the Simultaneous Suppression of BCR/ABL and BCR/ABL– independent Signals

Activating PP2A Tumor Suppressor Activity as a Potential Therapy for Treating Jak2 V617F-Driven Myeloproliferative Disorders.

Requirement of the E2F3 Transcription Factor for BCR/ABL Leukemogenesis.

FTY720 (2-Amino-2-[2-(4-octylphenyl) ethyl] Propane 1, 3-diol hydrochloride), Mediates Cytotoxicity through Caspase Independent and Protein Phosphatase 2A Dependent Mechanisms in Chronic Lymphocytic Leukemia and Lymphoblastic Leukemia/Lymphoma.

Molecular and Pharmacologic Suppression of MAPK Activity Rescues Differentiation of BCR/ABL + Myeloid Progenitors by Releasing C/EBPa from the Inhibitory Effect of hnRNP E2.

ReSETting PP2A Tumor Suppressor Activity Overcomes BCR/ABL Leukemogenic Potential in Blast Crisis CML.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only